The World Health Organization (WHO) has unveiled a new initiative aiming to stop the further spread of Anopheles stephensi ...
NHS England has announced that specialist teams of volunteers will be touring England’s lung cancer hotspots with a ‘giant ...
InflaRx has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorisation (EUA) for ...
Envision Pharma Group is pleased to announce the appointment of Mel Formica as its Head of Envision Value & Access.
The event comes at an interesting time, especially in the UK where England’s Rare Diseases Action Plan 2022 was recently ...
Gilead Sciences (Gilead) has announced the completion of the previously announced transaction to acquire UK-based ...
Merck & Co – known as MSD outside the US and Canada – has announced its plans to initiate a new phase 3 clinical programme ...
The approval is specifically for Ultomiris as a treatment for adult patients who are anti-acetylcholine receptor (AChR) ...
AstraZeneca’s (AZ) Tezspire (tezepelumab) has been granted marketing authorisation in Great Britain by the Medicines and Healthcare products Regulatory Agency (MHRA) for use as an add-on maintenance ...
Tezspire (tezepelumab) has been approved by the European Commission (EC) for use as an add-on maintenance treatment in ...
Pfizer and Sangamo Therapeutics have reopened the recruitment of their phase 3 study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to ...
Bristol Myers Squibb (BMS) has announced positive results from a phase 3 trial evaluating Opdivo (nivolumab) as a single ...